Fish consumption, fish oil supplements and risk of atherosclerosis in the Tromsø study

Stein Harald Johnsen¹²*, Bjarne K. Jacobsen³, Sigrid K. Brækkan¹⁵, John-Bjarne Hansen⁴⁵ and Ellisiv B. Mathiesen¹²

Abstract

Background: Whether long-chain n-3 PUFAs of marine origin have an anti-atherogenic effect in the general population has hardly been studied. In this population-based study, we hypothesized that fatty fish and fish oil intake protect against development of novel atherosclerotic plaques and is associated with reduced plaque size.

Methods: We obtained questionnaire-based information on fish consumption and carotid ultrasonography from 3900 persons aged 45–74 years. The questionnaires were validated by measuring serum concentrations of PUFAs and triglycerides in a subgroup. At follow-up seven years later, 2983 (76%) went through a second ultrasound scanning. Logistic regression and general linear models were used to analyze the outcome (plaque presence and plaque area) as a function of fish consumption, including analyses stratified on fish oil supplements.

Results: At baseline, lean fish intake < 1 time/week vs. 1–1.9 times/week was associated with risk of plaque (OR 1.34, 95% CI 1.03–1.76). Fatty fish intake and use of fish oil supplements were not statistically significantly associated with atherosclerosis at baseline. In persons without plaque at baseline, total fish consumption ≥3 times/week vs. 1–1.9 times/week was associated with risk of novel plaque (OR 1.32, 95% CI 1.01–1.73) and larger plaque area (1.76 mm² vs. 1.46 mm², p = 0.02) at follow-up. Adjustments for use of fish oil supplements had no impact on the associations, and no interactions were seen between total, fatty or lean fish consumption and fish oil intake.

Conclusions: We found no protective effect of fatty fish eating or fish oil supplements on atherosclerotic plaque formation or plaque area in a general population. Lean fish consumption was associated with a reduced risk for plaque in cross-sectional analysis, suggesting that the beneficial effects of fish consumption on atherosclerosis may be mediated through other mechanisms than n-3 PUFAs.

Keywords: Atherosclerosis, Fish consumption, PUFAs, Carotid ultrasonography, Fish oil

Background

Epidemiological, animal, and cell culture studies show that long-chain n-3 PUFAs of marine origin, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA), reduce the risk of cardiovascular diseases (CVD). Fatty fish and fish oils are rich sources of these fatty acids. The most compelling evidence for cardiovascular benefits of n-3 PUFAs comes from 4 controlled trials of nearly 40,000 participants randomized to receive EPA with or without DHA in primary prevention [1], after myocardial infarction (MI) [2, 3], and in heart failure [4]. However, recent meta-analyses including newer randomized trials found that, except for a 10% reduction in sudden cardiac death among patients with prior MI, n-3 PUFA supplementation was not associated with a lower risk of all-cause mortality, non-fatal MI, or stroke [5, 6]. Taken together, the cumulative evidence suggests that n-3 PUFA supplements may reduce cardiac death in patients with prior MI, possibly through a reduction in ischemia-induced ventricular fibrillation [6]. In the recent updated advisory report, the American Heart Association has endorsed the use of n-3 PUFA at a dose of approximately 1 g/day, either in the form of fatty fish or fish oil supplements in patients with a previous MI or in...
patients with heart failure without preserved left ventricular function [6].

N-3 PUFAs can influence many aspects of the pathogenesis of CVD, including inflammation [7], arrhythmias [8–12], platelet aggregation [13, 14], hypertension [15–17], and hyperlipidemia [18–20]. Although most evidence points to an antiarrhythmic effect, several studies have suggested that n-3 PUFAs may also have favorable effects on the pathogenesis of atherosclerosis. Fish oil has prevented the development of experimental atherosclerosis in pigs and rhesus monkeys [21–23]. In humans, a case-control study on peripheral arterial disease found that plasma levels of DPA related inversely to blocked arteries [24]. Cross-sectional studies with carotid ultrasonography revealed that carotid artery wall thickness decreased with EPA, DHA and DPA intake [25, 26]. A population based prospective study of atherosclerosis in men aged 40–49 years showed that serum concentrations of n-3 PUFAs contributed to the difference incidence of coronary artery calcification between Japanese and US white men [27].

Whether any anti-atherosclerotic effects of fish consumption is due to biological effects of n-3 PUFAs, or fish intake itself, due to replacement of other less favorable foods, has not been clearly addressed. An observational study in postmenopausal women found that after 3.2 years of follow-up, the consumption of ≥2 servings of fish or ≥1 serving of tuna or dark fish each week was associated with less progression of coronary artery stenosis [28]. A recent Italian study of 961 persons aged 18–89 y without clinically known atherosclerotic disease found that consuming ≥2 vs. < 1 serving of fish weekly was protective against carotid atherosclerosis defined as common carotid intima media thickness (cIMT) ≥ 0.9 mm or a focal plaque of > 1.2 mm [29]. According to The European Society of Cardiology (ESC)/European Society of Hypertension (ESH) guidelines (2013) SCORE Chart, asymptomatic vascular damage is defined as the presence of IMT > 0.9 mm or a focal plaque.

In this observational population-based study, we investigated the association between habitual fish consumption, fish oil consumption and carotid atherosclerosis defined as the presence of plaques on ultrasound assessment. We hypothesized that fatty fish and fish oil intake protect against development of novel atherosclerotic plaques and is associated with reduced plaque size (area) at baseline and follow-up.

**Methods**

**Subjects**

For this study, we used cross-sectional and prospective data from the 4th (1994–95) and 5th survey (2001) of the Tromsø study [30]. In the 4th survey (baseline), valid information on carotid plaque number, plaque area and fish consumption was obtained in 4589 persons aged 45–74. We excluded 689 persons with previous angina pectoris, MI or stroke, leaving 3900 eligible for the present study. Valid information on fish oil supplements was available in 3290 participants. In the 5th survey (follow-up), 2983 out of the 3900 subjects (76%) underwent a new valid ultrasound scanning, in whom 2535 persons had valid information on fish oil supplements.

**Ethics**

The Norwegian Data Inspectorate licensed all data. The Regional Committee for Research Ethics approved the study (REC no. 200005785–7/IAY/400). All the participants gave their written informed consent.

**Assessment of fish consumption and fish oil supplements**

At baseline, information of weekly consumption of fish for dinner and intake of fish oil supplements was assessed through a self-administered questionnaire. For participants aged < 70 years, the questionnaire covered 37 food frequency items, whereas those aged ≥ 70 years filled in a simplified questionnaire that covered only 23 food frequency items. Participants were asked how many times per week they usually ate fatty and lean fish, respectively (in the analyses categorized into four groups: never, < 1 time/week, 1 time/week, ≥2 times/week). Total weekly consumption of fish (times per week) was calculated by combining the answers given to the fatty and lean fish questions, and categorized into the following categories: < 1 time/week, 1–1.9 times/week, 2–2.9 times/week, and ≥ 3 times/week. According to the Norwegian Directorate of Health, a normal serving size of fish is 150 g. Participants were additionally asked to report how many months during the last year they had taken fish oil supplements on a daily basis. Intake of fish oil supplements was categorized as “no supplements” (no months during last year) and “supplements” (any number of months during the last year). The validity and reproducibility of dietary data from self-administered questionnaires in the Tromsø cohort have been reported previously [31, 32]. Additionally for this study, we validated the questionnaire based dietary assessment on fish servings and fish oil supplementation in a subgroup of 1656 participants by measuring serum concentrations of n-3 PUFAs and exploring the expected triglyceride-lowering effect of n-3 PUFAs [33].

**Cardiovascular risk factors**

Height and weight were measured standardized. Body mass index (BMI) was calculated as weight in kilograms, divided by the square of height in meters (kg/m²). Specially trained personnel recorded blood pressure with an automatic device (Dinamap Vital Signs Monitor, Tampa Fla) with the participants in sitting position after...
2 min rest. Three readings of blood pressure (on the upper right arm) were taken, separated with a 1-min interval. We used the average of the last two measurements in the analyses. Non-fasting serum total cholesterol and triglycerides were analyzed by enzymatic colorimetric methods with commercial kits (CHOD-PAP for cholesterol and GPO-PAP for triglycerides; Boehringer-Mannheim). Serum HDL cholesterol was measured after precipitation of lower-density lipoprotein with heparin and manganese chloride. LDL cholesterol was estimated using the Friedewald equation. Fibrinogen was measured with the PT-Fibrinogen reagent (Instrumentation Laboratory). Monocytes and white blood cells were counted with automated cell counters by standard techniques. CRP was analyzed in thawed aliquots after storage at −70 °C with a particle-enhanced immunoturbidimetric assay on a Modular P with reagents from Roche Diagnostics (Roche, Mannheim, Germany). The Department of Clinical Chemistry, University Hospital of North Norway, did all the blood sample analyses. Information concerning education (in the analyses dichotomized to education at college/university level (yes/no)), leisure physical activity (sweating/out of breath ≥ 1 h/week (yes/no)), coffee consumption (cups/day), previous MI, prevalent angina pectoris and diabetes mellitus (yes/no), and cigarette smoking (never/previous/currently) was obtained from a questionnaire enclosed in the letter of invitation. We defined present coronary heart disease (CHD) as self-reported prevalent angina pectoris or previous MI.

Ultrasonography and measures of atherosclerosis
The ultrasound methods and reproducibility of carotid examination have been detailed elsewhere [34, 35]. At baseline and follow-up, we used identical ultrasound imaging system (Acuson Xp10 128, ART upgraded, with a 7.5-MHz linear-array transducer, aperture size 38 mm). Six locations in the right carotid artery (the far and near walls of the common carotid, the bulb, and the internal carotid) were scanned for the presence of plaque (yes/no) and the number of plaques were registered. In Adobe Photoshop v7.0, we analyzed still images of each plaque, and the area (mm²) was calculated. In participants with more than one plaque, the sum of plaque areas was taken as the total plaque area (TPA). Novel plaque formation was defined as ≥ one new plaque at follow-up in persons with no plaque at baseline. The difference in TPA between baseline and follow-up (ΔTPA) was calculated.

Statistics
Descriptive statistics (means or percentages) were computed for each independent baseline variable in categories of fish consumption. Presence of plaque and TPA were the dependent variables in the regression models. TPA at baseline and follow-up (but not ΔTPA) was square-root-transformed to approximate normal distribution. Fish consumption (total, fatty fish and lean fish) was the main explanatory variable. Predefined risk factors for atherosclerosis (systolic blood pressure, current smoking, total cholesterol, HDL-cholesterol, triglycerides, diabetes, leucocyte count, monocyte count, fibrinogen, CRP and anti-hypertensive medication) were introduced as co-variables to adjust for confounding. First, we analyzed the whole sample on fish consumption without fish oil in the models. Analyses were then repeated in models stratified by fish oil supplements (yes/no). Logistic regression and general linear models were used to model the outcome (plaque presence and TPA, respectively) as a function of fish consumption. Linear trends across level of fish intake were tested by logistic regression for categorical dependent variables and by linear regression for continuous dependent variables. Statistical analyses were conducted with SAS version 9.4 software (SAS Institute, Cary, NC), and two-sided P < 0.05 was considered statistically significant.

Results
Table 1 lists baseline characteristics in the different categories of fish servings. Elderly men consumed more fish than relatively younger women did. There was an inverse trend between the number of fish servings per week and serum triglycerides (p = 0.002). Leucocyte count was positively associated with fish consumption (p = 0.05). Participants who consumed fatty fish ≥ 2 times/week (n = 608) were older, more likely to be males, daily smokers, used more fish oil supplements and lipid-lowering drugs, and had higher levels of CRP (Table 2) than subjects with less frequent fatty fish intake. The use of fish oil supplements was associated with female sex, higher education, physical activity, not being a daily smoker, less boiled coffee drinking, as well as lower BMI, serum triglycerides, monocyte concentration, white cell count, fibrinogen and CRP (Table 3).

Fish consumption and risk for plaque and TPA at baseline
At baseline, at least one plaque was present in 1884 of the 3900 (48.3%) persons. There was a statistically significant inverse trend (p = 0.02) between lean fish intake and plaque prevalence (but not TPA). Lean fish intake < 1 time/week vs. 1–1.9 times/week was associated with 34% increased risk of plaque (OR 1.34, 95% CI 1.03–1.76), whereas no significant associations were found between total or fatty fish intake and plaque prevalence or TPA (Table 4). Among the 3290 persons with available information about the use of fish oil supplements, the age- and sex-adjusted plaque prevalence (47.3% vs. 47.9%, p = 0.7) and square-root-transformed TPA levels
At follow-up, at least one plaque was present in 1,869 of the 2,983 (62.7%) persons who had a new ultrasound scan. This includes subjects with a plaque present already at baseline and subjects with a novel plaque. Both total fish (p-trend = 0.05) and fatty fish (p-trend = 0.02) consumption were positively associated with plaque prevalence (but not with TPA). No associations were found between lean fish consumption and plaque prevalence or TPA (results not shown in table). Among the 2,535 persons with available information on fish oil supplements, the plaque prevalence (62.0% vs. 62.4%, p = 0.8) and square-root-transformed TPA levels (2.73 vs. 2.84 mm², p = 0.3) were similar in users and non-users. Also, the change in TPA (Δ TPA) between baseline and follow-up (5.84 vs. 6.00 mm², p = 0.8) was similar in users and non-users of fish oil supplements.

Of the 2016 persons with no plaque at baseline, 1,634 (81%) were re-examined at follow-up. At least one novel plaque had developed in 700 (42.8%) of these. The risk of novel plaque and TPA increased linearly by number of total fish servings (Table 5). Total fish intake ≥3 times/week vs. 1–1.9 times/week was associated with 32% higher risk of novel plaque (OR 1.32, 95% CI 1.01–1.73) and larger TPA (1.76 mm² vs. 1.46 mm²). Among the 1,400 persons with available information on use of fish oil supplements, the prevalence of novel plaque (44.0% vs. 41.7%, p = 0.4) and square-root-transformed TPA level (1.63 vs. 1.62 mm², p = 0.9) were similar in users and non-users of fish oil supplements.

Analyses adjusted for fish oil supplements
All analyses above were repeated in models restricted to subjects with available information about the use of fish oil supplements.
oil supplements. Adjustments for this variable had no impact on the associations, and no interactions were seen between total, fatty or lean fish consumption and fish oil intake.

**Discussion**

In this study, we found no protective effect of fatty fish intake or fish oil supplements on atherosclerosis assessed by carotid ultrasound. If anything, the association was positive. At baseline (Table 4), we found that lean fish consumption, if anything, reduced the odds of having carotid plaque. However, in prospective analyses, this finding could not be reproduced and total fish intake was actually associated with an increased risk of novel plaque formation in persons without pre-existing plaque.

As expected, we found an inverse trend between total fish consumption and serum triglycerides (Table 1) and that fish oil supplements were associated with low triglycerides (Table 3). However, no statistically significant inverse relationship was found between the intake of fatty fish and serum triglyceride levels. High triglycerides are not directly atherogenic, but represent an important biomarker of cardiovascular risk because of their association with atherogenic VLDL remnant particles.
A small randomized trial (n = 59) did not detect significant effects of fish oil supplementation (6 g/day for 2.3 years) on the progression of coronary atherosclerosis as measured by coronary angiography [37]. A larger randomized trial (n = 223) found modest effects of fish oil supplementation (1.65 g/day for two years) on coronary atherosclerosis as measured by coronary angiography [38], but not on carotid atherosclerosis as measured by ultrasound [39]. A third open-label randomized trial evaluated the effects of EPA (1.8 g/day for 2.1 years) on progression of carotid atherosclerosis in 81 Japanese patients with type 2 diabetes. Individuals randomized to EPA had less progression of both mean and maximal intimal medial thickness [40]. Although these small clinical studies suggest that fish oil consumption may modestly reduce progression of atherosclerosis, we could not reproduce this effect in a large general population. When looking closer into the 541 participants who consumed fatty fish ≥2 times/week (Table 2), we found that they were older, were more likely to be males and smokers, and had higher levels of CRP. On the other hand, users of fish oil supplement had a more favorable risk factor profile compared to non-users, implying that those who take fish oil supplements have a healthier lifestyle.

An interesting question is whether fish consumption itself, independent of n-3 PUFAs, can protect against atherosclerosis due to replacement of other less healthy foods. It is now increasingly recognized that the beneficial effects of fish consumption is not limited to lipids and fatty acids, but that the peptides and amino acids like taurine and glycine, together with vitamins, are also important for disease prevention [41]. Lean fish contains

and apo C-III, a proinflammatory, proatherogenic protein found on all classes of the plasma lipoproteins [36].

Unexpectedly, we found no protective effect of fatty fish intake or fish oil supplements, both containing high amounts of n-3 PUFAs, on the risk for atherosclerosis. The evidence for an anti-atherogenic effect of n-3 PUFAs is admittedly not very strong. The studies that have shown effects are in general small, cross-sectional, have reported on cIMT and not plaque, or have been conducted in patients with previous CVD or high risk for CVD. A small randomized trial (n = 59) did not detect significant effects of fish oil supplementation (6 g/day for 2.3 years) on the progression of coronary atherosclerosis as measured by coronary angiography [37]. A larger randomized trial (n = 223) found modest effects of fish oil supplementation (1.65 g/day for two years) on coronary atherosclerosis as measured by coronary angiography [38], but not on carotid atherosclerosis as measured by ultrasound [39]. A third open-label randomized trial evaluated the effects of EPA (1.8 g/day for 2.1 years) on progression of carotid atherosclerosis in 81 Japanese patients with type 2 diabetes. Individuals randomized to EPA had less progression of both mean and maximal intimal medial thickness [40]. Although these small clinical studies suggest that fish oil consumption may modestly reduce progression of atherosclerosis, we could not reproduce this effect in a large general population. When looking closer into the 541 participants who consumed fatty fish ≥2 times/week (Table 2), we found that they were older, were more likely to be males and smokers, and had higher levels of CRP. On the other hand, users of fish oil supplement had a more favorable risk factor profile compared to non-users, implying that those who take fish oil supplements have a healthier lifestyle.

An interesting question is whether fish consumption itself, independent of n-3 PUFAs, can protect against atherosclerosis due to replacement of other less healthy foods. It is now increasingly recognized that the beneficial effects of fish consumption is not limited to lipids and fatty acids, but that the peptides and amino acids like taurine and glycine, together with vitamins, are also important for disease prevention [41]. Lean fish contains

and apo C-III, a proinflammatory, proatherogenic protein found on all classes of the plasma lipoproteins [36].

Unexpectedly, we found no protective effect of fatty fish intake or fish oil supplements, both containing high amounts of n-3 PUFAs, on the risk for atherosclerosis. The evidence for an anti-atherogenic effect of n-3 PUFAs is admittedly not very strong. The studies that have shown effects are in general small, cross-sectional, have reported on cIMT and not plaque, or have been conducted in patients with previous CVD or high risk for CVD. A small randomized trial (n = 59) did not detect significant effects of fish oil supplementation (6 g/day for 2.3 years) on the progression of coronary atherosclerosis as measured by coronary angiography [37]. A larger randomized trial (n = 223) found modest effects of fish oil supplementation (1.65 g/day for two years) on coronary atherosclerosis as measured by coronary angiography [38], but not on carotid atherosclerosis as measured by ultrasound [39]. A third open-label randomized trial evaluated the effects of EPA (1.8 g/day for 2.1 years) on progression of carotid atherosclerosis in 81 Japanese patients with type 2 diabetes. Individuals randomized to EPA had less progression of both mean and maximal intimal medial thickness [40]. Although these small clinical studies suggest that fish oil consumption may modestly reduce progression of atherosclerosis, we could not reproduce this effect in a large general population. When looking closer into the 541 participants who consumed fatty fish ≥2 times/week (Table 2), we found that they were older, were more likely to be males and smokers, and had higher levels of CRP. On the other hand, users of fish oil supplement had a more favorable risk factor profile compared to non-users, implying that those who take fish oil supplements have a healthier lifestyle.

An interesting question is whether fish consumption itself, independent of n-3 PUFAs, can protect against atherosclerosis due to replacement of other less healthy foods. It is now increasingly recognized that the beneficial effects of fish consumption is not limited to lipids and fatty acids, but that the peptides and amino acids like taurine and glycine, together with vitamins, are also important for disease prevention [41]. Lean fish contains

and apo C-III, a proinflammatory, proatherogenic protein found on all classes of the plasma lipoproteins [36].

Unexpectedly, we found no protective effect of fatty fish intake or fish oil supplements, both containing high amounts of n-3 PUFAs, on the risk for atherosclerosis. The evidence for an anti-atherogenic effect of n-3 PUFAs is admittedly not very strong. The studies that have shown effects are in general small, cross-sectional, have reported on cIMT and not plaque, or have been conducted in patients with previous CVD or high risk for CVD. A small randomized trial (n = 59) did not detect significant effects of fish oil supplementation (6 g/day for 2.3 years) on the progression of coronary atherosclerosis as measured by coronary angiography [37]. A larger randomized trial (n = 223) found modest effects of fish oil supplementation (1.65 g/day for two years) on coronary atherosclerosis as measured by coronary angiography [38], but not on carotid atherosclerosis as measured by ultrasound [39]. A third open-label randomized trial evaluated the effects of EPA (1.8 g/day for 2.1 years) on progression of carotid atherosclerosis in 81 Japanese patients with type 2 diabetes. Individuals randomized to EPA had less progression of both mean and maximal intimal medial thickness [40]. Although these small clinical studies suggest that fish oil consumption may modestly reduce progression of atherosclerosis, we could not reproduce this effect in a large general population. When looking closer into the 541 participants who consumed fatty fish ≥2 times/week (Table 2), we found that they were older, were more likely to be males and smokers, and had higher levels of CRP. On the other hand, users of fish oil supplement had a more favorable risk factor profile compared to non-users, implying that those who take fish oil supplements have a healthier lifestyle.

An interesting question is whether fish consumption itself, independent of n-3 PUFAs, can protect against atherosclerosis due to replacement of other less healthy foods. It is now increasingly recognized that the beneficial effects of fish consumption is not limited to lipids and fatty acids, but that the peptides and amino acids like taurine and glycine, together with vitamins, are also important for disease prevention [41]. Lean fish contains

and apo C-III, a proinflammatory, proatherogenic protein found on all classes of the plasma lipoproteins [36].

Unexpectedly, we found no protective effect of fatty fish intake or fish oil supplements, both containing high amounts of n-3 PUFAs, on the risk for atherosclerosis. The evidence for an anti-atherogenic effect of n-3 PUFAs is admittedly not very strong. The studies that have shown effects are in general small, cross-sectional, have reported on cIMT and not plaque, or have been conducted in patients with previous CVD or high risk for CVD. A small randomized trial (n = 59) did not detect significant effects of fish oil supplementation (6 g/day for 2.3 years) on the progression of coronary atherosclerosis as measured by coronary angiography [37]. A larger randomized trial (n = 223) found modest effects of fish oil supplementation (1.65 g/day for two years) on coronary atherosclerosis as measured by coronary angiography [38], but not on carotid atherosclerosis as measured by ultrasound [39]. A third open-label randomized trial evaluated the effects of EPA (1.8 g/day for 2.1 years) on progression of carotid atherosclerosis in 81 Japanese patients with type 2 diabetes. Individuals randomized to EPA had less progression of both mean and maximal intimal medial thickness [40]. Although these small clinical studies suggest that fish oil consumption may modestly reduce progression of atherosclerosis, we could not reproduce this effect in a large general population. When looking closer into the 541 participants who consumed fatty fish ≥2 times/week (Table 2), we found that they were older, were more likely to be males and smokers, and had higher levels of CRP. On the other hand, users of fish oil supplement had a more favorable risk factor profile compared to non-users, implying that those who take fish oil supplements have a healthier lifestyle.

An interesting question is whether fish consumption itself, independent of n-3 PUFAs, can protect against atherosclerosis due to replacement of other less healthy foods. It is now increasingly recognized that the beneficial effects of fish consumption is not limited to lipids and fatty acids, but that the peptides and amino acids like taurine and glycine, together with vitamins, are also important for disease prevention [41]. Lean fish contains
less energy than fatty fish and has been associated with less risk for metabolic syndrome [42]. At baseline, we found that consumption of lean fish, which contains very low levels of n-3 PUFAs, was inversely associated to plaque prevalence, and that the effect remained significant after adjustment for fish oil supplements. These findings suggest that mechanisms other than those mediated through fatty acids from fish consumption may be of importance.

Studies have suggested that the preparation method, frying in particular, may substantially alter the fatty acid content of a fishmeal [43]. A study by Mozaffarian et al. found that fried fish and fish sandwich consumption was not associated with lower risk for ischemic heart disease, arrhythmic death, or nonfatal myocardial infarction but rather with trends towards higher risk [44]. In addition, data from the Multi-Ethnic Study of Atherosclerosis showed that the dietary intake of non-fried fish was inversely associated with the prevalence of subclinical atherosclerosis defined as thickening of the common carotid intima media thickness [45]. Unfortunately, we lack specific registrations of differences in fish cooking procedures and nutrients that may influence the impact of fish intake.

Strengths of this study include the prospective design and a large general population with high attendance rate. As persons with cardiovascular diseases are more likely to have carotid plaque when compared to those without and at the same time might eat more fish for their vascular health, we excluded all participants with previous angina, MI and stroke to minimize confounding. We further validated the reliability of dietary assessment on fish servings and fish oil supplementation by measuring serum concentrations of n-3 PUFAs and exploring the expected triglyceride-lowering effect of n-3 PUFAs. Plaque presence and plaque area are considered as more robust measures of subclinical atherosclerosis than cIMT [46].

The study also has limitations, however. First, residual confounding can be expected. Even though we excluded persons with previous cardiovascular diseases, and made multiple adjustments, differences in lifestyle between groups may have biased the associations between fish consumption and atherosclerosis. Second, particularly regarding the relationships between fish intake and the risk of novel plaques, several of the risk factors may have changed over time, including fish consumption, which may lead to non-differential misclassification, and thereby underestimation of the true associations. Third, we lack specific registrations of differences in fish cooking procedures and nutrients that may influence the impact of fish intake.

Table 5 Risk for plaque and total plaque area at follow-up in persons with no plaque present at baseline, according to categories of fish consumption: the Tromsø Study

| Fish servings (times/wk) | N | Novel plaque N (%) | Risk for plaque OR (95% CI) | TPA* mm² (SE) |
|-------------------------|---|---------------------|-----------------------------|--------------|
| Total fish              |   |                     |                             |              |
| < 1                     | 116 | 44 (37.9)           | 0.98 (0.62–1.54)            | 1.52 (0.19)  |
| 1–1.9                   | 596 | 225 (37.8)          | 1 (Reference)              | 1.46 (0.08)  |
| 2–2.9                   | 416 | 181 (43.5)          | 1.15 (0.87–1.52)           | 1.62 (0.10)  |
| ≥ 3                     | 506 | 250 (49.4)          | 1.32 (1.01–1.73)           | 1.76 (0.09)  |
| p-trend                 |   |                     |                             |              |
| Fatty fish              |   |                     |                             |              |
| < 1                     | 829 | 332 (40.1)          | 0.90 (0.72–1.13)           | 1.54 (0.07)  |
| 1–1.9                   | 631 | 280 (44.4)          | 1 (Reference)             | 1.63 (0.08)  |
| ≥ 2                     | 174 | 88 (50.6)           | 1.18 (0.81–1.72)           | 1.75 (0.16)  |
| p-trend                 |   |                     |                             |              |
| Lean fish               |   |                     |                             |              |
| < 1                     | 142 | 55 (38.7)           | 0.99 (0.65–1.49)           | 1.57 (0.17)  |
| 1–1.9                   | 636 | 253 (39.8)          | 1 (Reference)             | 1.52 (0.08)  |
| ≥ 2                     | 856 | 392 (45.8)          | 1.12 (0.89–1.41)           | 1.66 (0.07)  |
| p –trend                |   |                     |                             |              |

Models were adjusted for age, sex, systolic blood pressure, current smoking, total cholesterol, HDL-cholesterol, triglycerides, diabetes, leucocyte count, monocyte count, fibrinogen, CRP and anti-hypertensive medication

TPA Total plaque area

*Square root transformed
into our estimated models. A weakness of the study is related to loss of follow-up, which may have attenuated the results. Although we used a standardized protocol for the measurement of plaque at both baseline and follow-up, plaque assessment may be distorted by measurement error. Plaques of low echogenicity may have been overlooked. Any such misclassification is expected to underestimate the true association.

Conclusions
In conclusion, we found no protective effect of fatty fish consumption or use of fish oil supplements on risk of atherosclerosis. In cross-sectional analyses, we found a preventive effect of lean fish eating on atherosclerotic plaque prevalence. The findings suggest that the beneficial effects of fish consumption on atherosclerosis may be mediated through other mechanisms than n-3 PUFAs.

Abbreviations
BMI: Body mass index; CHD: Coronary heart disease; cIMT: Carotid intima media thickness; CRP: C-reactive protein; CVD: Cardiovascular diseases; DHA: Docosahexaenoic acid; DPA: Docosapentaenoic acid; EPA: Eicosapentaenoic acid; HDL: High density lipoprotein; LDL: Low density lipoprotein; MI: Myocardial infarction; PUFA: Polyunsaturated fatty acids; TPA: Total plaque area; VLDL: Very low density lipoprotein

Acknowledgements
The data delivery costs were funded by a grant from the research fund of the Department of Neurology, University Hospital of North Norway.

Funding
The publication charges for this article have been funded by a grant from the publication fund of UiT the Arctic University of Norway.

Availability of data and materials
All enquiries about the Tromsø Study should be sent by e-mail to: tromsous@ism.uit.no

Authors’ contributions
The authors’ responsibilities were as follows: SHJ carried out ultrasonographic measurements, performed data analysis and interpretation and drafted the manuscript. BJK critically revised the manuscript for important intellectual content. SKB revised the manuscript. JBH participated in its design and coordination and revised the manuscript. EM conceived of the study and participated in its design and coordination. All authors have read and approved the final manuscript.

Ethics approval and consent to participate
The Norwegian Data Inspectorate licensed all data. The Regional Committee for Research Ethics approved the study (REC no. 200005785–7/AY/400). All the participants gave their written informed consent.

Consent for publication
All the participants gave their written informed consent for publication of the data.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Neurology, University Hospital of North Norway, Sykehusvegen 38, 9019 Tromsø, Norway. 2Brain and Circulation Research Group, Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway. 3Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway. 4K. G. Jebsen TREC – Thrombosis Research and Expertise Center, Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway. 5Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway.

Received: 17 November 2017 Accepted: 14 May 2018
Published online: 25 May 2018

References
1. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Okawa S, Sasai J, Hishida H, Itakura H, Kita T, Katabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090–8.
2. Burr ML, Fehily AM, Gilbert JF, Rogers S, Hilliday RM, Sweetnam PM, Elwood PC, Deadman NM. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and Reinforcement trial (DART). Lancet. 1989;2:757–61.
3. GISSI-Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopraovivenza nell’Infarto Miocardico). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 1999;354(9177):447–55.
4. Tavazzi L, Magnioli AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G, GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet. 2008;372:1223–30.
5. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elafso MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA. 2012;308:1024–33. https://doi.org/10.1001/2012.jama.11374.
6. Siscovick DS, Barringan TA, Frettis AM, Wu JH, Lichtenstein AH, Costello RB, Kris-Etherton PM, Jacobson TA, Engler MB, Alger HM, Appel LJ, Mcoaffarian D, American Heart Association Nutrition Committee of the Council on Lifestyle and Cardiovascular Health, Council on Epidemiology and Prevention, Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology. Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of cardiovascular disease: a science advisory from the American Heart Association Circulation. 2017;135(18):867–84. https://doi.org/10.1161/CIR.0000000000000482.
7. De Caterina R, Liao JK, Libby P. Fatty acid modulation of endothelial activation. Am J Clin Nutr. 2002;71(Suppl):213S–23S.
8. McLennan PL, Bridle TM, Abeywardena MY, Charnock JS. Dietary lipid modulation of ventricular fibrillation threshold in the mammoset monkey. Am Heart J. 1992;123:555–61.
9. Billman GE, Hallaq H, Leaf A. Prevention of ischemia-induced ventricular fibrillation by ω-3 fatty acids. Proc Natl Acad Sci U S A. 1994;91:4427–30.
10. Siscovick DS, Raphanathan TE, King I, Weinmann S, Wicklund KG, Albright J, Bovbjerg V, Arbogast P, Smith H, Kush L. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA. 1995;274:1363–7.
11. Albert CM, Hennekens CH, O’Donnell CJ, Ajanu UA, Carey VJ, Willett WC, Rusklin JW, Manson JE. Fish consumption and risk of sudden cardiac death. JAMA. 1998;279:23–8.
12. Albert CM, Campos H, Stampfer MJ, Ridker PM, Manson JE, Willett WC, Ma J. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med. 2002;346:1113–8. https://doi.org/10.1056/NEJMoa012198.
13. Lorenz R, Spengler U, Fisher S, Ohm J, Weber PC. Platelet function, thromboxane formation and blood pressure control during supplementation of the western diet with cod liver oil. Circulation. 1983;76:504–11.
14. Mortensen JZ, Schmidt EB, Nielsen AH, Dyeberg J. The effect of n-6 and n-3 polyunsaturated fatty acids on hemostasis, blood lipids and blood pressure. Thromb Haemost. 1983;50:43–6.
15. Banaa KH, Bjønne KS, Straume B, Gram NT, Thelle D. Effect of eicosapentaenoic and docosahexaenoic acids on blood pressure in hypertension. A population-based intervention trial from the Tromsø study. N Engl J Med. 1990;322:795–801. https://doi.org/10.1056/NEJM199005223221202.

16. Knapp HR, FitzGerald GA. The antihypertensive effect of fish oil: a controlled study of polysaturated fatty acid supplements in essential hypertension. N Engl J Med. 1989;320:1037–43.

17. Norris PG, Jones CJH, Weston MJ. Effect of dietary supplementation with fish oil on systolic blood pressure in mild essential hypertension. Br Med J. 1986;293:104–5.

18. Rader DJ. Effects of nonstatin lipid drug therapy on high-density lipoprotein metabolism. Am J Cardiol. 2009;103(Suppl. 1):18–23. https://doi.org/10.1016/j.amjcard.2008.12.018.

19. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106:2747–57.

20. Harris WS. N-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr. 1997;65(Suppl):1645S–54S.

21. Barbeau ML, Klemp KF, Guyton JR, Rogers KA. Dietary fish oil. Influence on lesion regression in the porcine model of atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17:688–94.

22. Weiner BH, Ockene IS, Levine PH, Cuénoud HF, Fisher M, Johnson BF, Mautner FH, Wilsgaard T, Njølstad I. Cohort profile: the Tromsø study. J Nutr. 2014;144:861–5.

23. Jacobsen BK, Bønaa KH. The reproducibility of dietary data from a self-administered questionnaire. The Tromsø study. Int J Epidemiol. 2012;41:161–7. https://doi.org/10.1093/ije/dyr049.

24. Jacobsen BK, Knutsen SF, Knutsen R. The Tromsø heart study: comparison of information from a short food frequency questionnaire with a dietary history survey. Scand J Soc Med. 1987;15:41–7.

25. Barbeau ML, Klemp KF, Guyton JR, Rogers KA. Dietary fish oil. Influence on lesion regression in the porcine model of atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17:688–94.

26. Hino A, Adachi H, Toyomasu K, Yoshida N, Hiratsuka A, Hirai Y, Satoh A, Imaizumi T. Very long chain n-3 fatty acids intake and carotid atherosclerosis: an epidemiological study evaluated by ultrasonography. Atherosclerosis. 2004;176:145–9.

27. Sekikawa A, Curb JD, Ueshima H. Matrine-derived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American, and white men: a cross-sectional study. J Am Coll Cardiol. 2008;52:417–24.

28. Sekikawa A, Miura K, Lee S, Fujiyoshi A, Edmundowicz D, Kadowaki T, Lee RE, Kadowaki S, Sutton-Tyrrell K, Okamura T, Bertolet M, Masaki KH, Parise H, Kuller LH, Ueshima H. Long chain n-3 polyunsaturated fatty acids and fish in relation to measurements of subclinical atherosclerosis. Am J Clin Nutr. 2008;88:1111–8.

29. Buscemi S, Nicolucci A, Luciano G, Galvano F, Grosso G, Belmonte S, Sprini D, Migliaccio S, Cianferotti L, Brandi ML, Rini GB. Habitual fish intake in postmenopausal women with coronary artery disease. Am J Clin Nutr. 2004;65(Suppl):1645S–54S.

30. Jacobsen BK, Eggen AE, Mathiesen ER, Wilsgaard T, Njalstad I. Cohort profile: the Tromsø study. Int J Epidemiol. 2012;41:161–7. https://doi.org/10.1093/ije/dyr049.

31. Jacobsen BK, Knutsen SF, Knutsen R. The Tromsø heart study: comparison of information from a short food frequency questionnaire with a dietary history survey. Scand J Soc Med. 1987;15:41–7.

32. Jacobsen BK, Banaa KH. The reproducibility of dietary data from a self-administered questionnaire. The Tromsø Study. Int J Epidemiol. 1990;19:349–53.

33. Hansen-Kone U, Enga KS, Sudduth-Klingner JM, Mathiesen EB, Njalstad I, Wilsgaard T, Watkins S, Brøkkland SK, Hansen JB. High fish plus fish oil intake is associated with slightly reduced risk of venous thromboembolism: the Tromsø study. J Nutr. 2014;144:861–7.

34. Joakimson O, Banaa KH, Stensland-Bugge E. Reproducibility of ultrasound assessment of carotid plaque occurrence, thickness, and morphology. The Tromsø Study. Stroke. 1997;28:2201–7.

35. Froese E, Johnson SH, Stensland-Bugge E, Joakimson O, Mathiesen EB, Arnesen E, Njalstad I. Repeated visual and computer-assisted carotid plaque characterization in a longitudinal population-based ultrasound study: the Tromsø study. Ultrasound Med Biol. 2003;29:323–11.

36. Talayero BG, Sacks FM. The role of triglycerides in atherosclerosis. Curr Cardiol Rep. 2011;13:544–52.

37. Sacks FM, Stone PH, Gibson CM, Silverman DI, Rosner B, Pasternak RC. Controlled trial of fish oil for regression of human coronary atherosclerosis. HARP research group. J Am Coll Cardiol. 1995;25:1492–8.

38. von Schacky C, Angerer P, Kothny W, Theisen K, Mudra H. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999;130:554–62.

39. Angerer P, Kothny W, Stork S, von Schacky C. Effect of dietary supplementation with omega-3 fatty acids on progression of atherosclerosis in carotid arteries. Cardiovasc Res. 2002;54:183–90.

40. Mita T, Watada H, Oghira T, Nomiya T, Oigawa O, Kinoshita J, Shimizu T, Hirose T, Tanaka Y, Kawamori R. Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes. Atherosclerosis. 2007;191:162–7.

41. Jensen I-I, Walquist M, Liaset B, Eveloov EE, Erlsetsen K-E. Dietary intake of cod and scallop reduces atherosclerotic burden in female apolipoprotein E deficient mice fed a western-type high fat diet for 13 weeks. Nutr Metab (Lond). 2016;13:8. https://doi.org/10.1186/s12976-016-0068-z.

42. Tamis C, Molin M, Civanicarova MS. Lean fish consumption is associated with lower risk of metabolic syndrome: a Norwegian cross sectional study. BMC Public Health. 2016;16:347. https://doi.org/10.1186/s12889-016-0134-0.

43. Candela M, Astiasaran L, Bello J. Deep-fat frying modifies high-fat fish lipid fraction. J Agric Food Chem. 1998;46:2793–6.

44. Mozaffarian D, Lernmait RN, Kuller LH, Burke GL, Tracy RP, Siscovick DS. Cardiac benefits of fish consumption may depend on the type of fish meal consumed: the cardiovascular health study. Circulation. 2003;107:1372–7.

45. He K, Liu K, Daviglus ML, Mayer-Davis E, Jenny NS, Jiang R, Ouyang P, Steffen LM, Siscovick D, Wu C, Barr RG, Tsai M, Burke GL. Intakes of long-chain n-3 polyunsaturated fatty acids and fish in relation to measurements of subclinical atherosclerosis. Am J Clin Nutr. 2008;88:1111–8.

46. Spence JD, Elasizm M, Díccico M, Hackam DG, Gall R, Lohmann T. Carotid plaque area: a tool for targeting and evaluating vascular preventive therapy. Stroke. 2003;34:2916–22.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more at biomedicalcentral.com/submissions